Navigation Links
BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:10/31/2008

ion or $0.32 per share.

As of September 30, 2008, the Company held cash, cash equivalents and investments of $67.9 million.

Year-to-Date 2008 Financial Results

Collaborative and other research and development revenues were $22.3 million for the nine months ended September 30, 2008, compared to $43.1 million for the nine months ended September 30, 2007. This decrease is driven by a reduction in peramivir related clinical development costs leading to a reduction in costs and associated revenue from HHS, plus the $4.9 million reserve taken in the second quarter of 2008 for amounts BioCryst previously expected to receive from HHS related to costs incurred in the Phase 3 program in intramuscular peramivir for outpatient influenza. These costs were associated with the Phase 3 program for peramivir that was voluntarily discontinued earlier this year and reimbursement of these costs is under discussion with HHS.

R&D expenses were $51.3 million for the nine months ended September 30, 2008, compared to $64.9 million for the nine months ended September 30, 2007. The decrease in R&D expenses is due to a reduction in the clinical development costs and toxicology costs associated with the peramivir program and a reduction in manufacturing costs associated with both the peramivir and forodesine HCl programs. These reductions were partially offset by an increase in the Company's clinical development costs for forodesine HCl and increases in personnel related costs and professional services.

G&A expenses were $8.0 million for the nine months ended September 30, 2008, compared to $7.0 million for the nine months ended September 30, 2007. The higher expenses were primarily due to an increase in professional fees and personnel related costs.

The net loss for the nine months ended September 30, 2008 was $34.8 million, or $0.91 per share, compared to a net loss for the nine months ended September 30, 2007 of $26.8 million or $0.86 per share.


'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
2. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
3. BioCryst to Present at the JMP Healthcare Focus Conference
4. BioCryst to Present at UBS 2008 Global Life Sciences Conference
5. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
6. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
9. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
10. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
11. BioCryst to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2015)... Brooklyn, NY (PRWEB) , ... July 06, 2015 , ... ... spectrophotometers. If a user had a high-end machine such as a Varian Cary 4000-7000, ... charm. So widespread was this design that even NIST used them for their SRM-2031 ...
(Date:7/3/2015)... ... July 03, 2015 , ... The Alexander Group, a 30-year ... industries alike-- typically known for its consummate professionalism-- embarks each year in a ... break from their day jobs. , "Our motto has always been work hard ...
(Date:7/3/2015)... Forskere kan søke ... Science", som finner sted i ... på  http://www.openinnovationinscience.at , og søknadsperioden varer frem ... to største utfordringene innen helsevitenskapen er mangelen ... og kompleksiteten av nåværende forskningsresultater, i følge ...
(Date:7/2/2015)... ... ... have been used in countless labs for decades. In the past, people had to ... expected, this was a daunting and tiring process looking at endless data tables and charts. ... navigate the complex catalog structure. , Now thanks to FireflySci, scientists are throwing away those ...
Breaking Biology Technology:FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 2FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 3The Alexander Group Declares Their Independence with a Bit of Levity 2Lansering av verdens første Open Innovation-program for utdanning av forskere 2Lansering av verdens første Open Innovation-program for utdanning av forskere 3New Cuvette E-Commerce Website Launched by FireflySci 2
... 30 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced ... ended September 30,2007. Third Quarter Highlights, - ... combination REOLYSIN(R) and radiation trial ... - including partial and remote responses in patients ...
... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) will be ... 2007 at 9:30 a.m. PT in San Diego. Daniel ... be providing a corporate overview. The live presentation ... following the event. The webcast and recording will be ...
... Neurocrine Biosciences,Inc. (Nasdaq: NBIX ) announced today that ... after the Nasdaq market closes on Thursday,November 1, 2007. ... at 5:00,p.m. Eastern Time (2:00 p.m. Pacific Time). ... (US) or 785-424-1052 (International) using the conference,ID: 7NBIX. The ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 2Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 3Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 4Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 5Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 6Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 7Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 8Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 9Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 10Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 11Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 12Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 13Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 14Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 15Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 16Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 17Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 18Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 19Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 20Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 21Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 22Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 23Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 24Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 25Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 26Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 27Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 28Oncolytics Biotech Inc. Announces 2007 Third Quarter Results 29
(Date:6/24/2015)... June 24, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Sharp has selected its ... authentication for its latest flagship smartphone device, the ... 200 million shipments of its fingerprint ID sensor ... strength, scalability and leadership in the biometrics market ...
(Date:6/23/2015)... June 23, 2015   Valencell, a ... results of a recent study that illustrates its ... wrist during activity. In a study conducted at ... along with the Apple Watch against a chest ... rate during activity. The study demonstrated that Valencell,s ...
(Date:6/17/2015)... Germany , June 17, 2015 ... QIA) today launched new Investigator ® STR assay kits ... the United States . The new genetic fingerprint ... genomic markers (short tandem repeats or STRs) for DNA matching. ... the quality of DNA in each sample, a novel QIAGEN ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... Westminster, Colo. (August 5, 2010) With global ... it could be reassuring to know that some creatures ... their current ones become less hospitable. Nevertheless, natural relocation ... for granted, according to Jessica Hellmann, Associate Professor at ...
... Elsevier Properties SA is pleased to congratulate Dr. Scott Stewart ... Athel Beckwith Lectureship, sponsored by Reaxys. The award is ... their first academic or industrial position within the past five ... the opportunity to present a lecture in at least six ...
... by an ancient glacier that once covered the summit of ... evidence of the extraordinary power and reach of global ... system that could happen again and continues to be a ... geochemical clues near the summit of Mauna Kea that tell ...
Cached Biology News:Butterflies shed light on how some species respond to global warming 2Butterflies shed light on how some species respond to global warming 3Elsevier congratulates Royal Australian Chemical Institute's Athel Beckwith Lectureship winner 2Ancient Hawaiian glaciers reveal clues to global climate impacts 2Ancient Hawaiian glaciers reveal clues to global climate impacts 3
... MagicMark and MagicMark XP Western ... easy and convenient protein molecular weight ... standard protein contains an IgG binding ... same antibody-conjugate reagents used to detect ...
... TOPO Cloning is the ... for cloning PCR products. ... Zero Blunt TOPO vectors ... activated with topoisomerase I. ...
... Production Conjugated peptides or recombinant ... protocol to produce antibodies in 2 rabbits. ... ELISA test until the titer reaches 1:4,000 ... titer Protein G purification Antibodies are ...
... Clone/PAD: ZMD.420. Immunogen: ... Specificity: Specific for the ... Reactivity: Human (positive control: ... Based on sequence homology reactivity ...
Biology Products: